These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 22885136)

  • 1. A computational neurodegenerative disease progression score: method and results with the Alzheimer's disease Neuroimaging Initiative cohort.
    Jedynak BM; Lang A; Liu B; Katz E; Zhang Y; Wyman BT; Raunig D; Jedynak CP; Caffo B; Prince JL;
    Neuroimage; 2012 Nov; 63(3):1478-86. PubMed ID: 22885136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A computational method for computing an Alzheimer's disease progression score; experiments and validation with the ADNI data set.
    Jedynak BM; Liu B; Lang A; Gel Y; Prince JL;
    Neurobiol Aging; 2015 Jan; 36 Suppl 1():S178-84. PubMed ID: 25444605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease progression timeline estimation for Alzheimer's disease using discriminative event based modeling.
    Venkatraghavan V; Bron EE; Niessen WJ; Klein S;
    Neuroimage; 2019 Feb; 186():518-532. PubMed ID: 30471388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analyzing the effect of APOE on Alzheimer's disease progression using an event-based model for stratified populations.
    Venkatraghavan V; Klein S; Fani L; Ham LS; Vrooman H; Ikram MK; Niessen WJ; Bron EE;
    Neuroimage; 2021 Feb; 227():117646. PubMed ID: 33338617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.
    Hampel H; Bürger K; Teipel SJ; Bokde AL; Zetterberg H; Blennow K
    Alzheimers Dement; 2008 Jan; 4(1):38-48. PubMed ID: 18631949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects.
    Trojanowski JQ; Vandeerstichele H; Korecka M; Clark CM; Aisen PS; Petersen RC; Blennow K; Soares H; Simon A; Lewczuk P; Dean R; Siemers E; Potter WZ; Weiner MW; Jack CR; Jagust W; Toga AW; Lee VM; Shaw LM;
    Alzheimers Dement; 2010 May; 6(3):230-8. PubMed ID: 20451871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study.
    Varma VR; Oommen AM; Varma S; Casanova R; An Y; Andrews RM; O'Brien R; Pletnikova O; Troncoso JC; Toledo J; Baillie R; Arnold M; Kastenmueller G; Nho K; Doraiswamy PM; Saykin AJ; Kaddurah-Daouk R; Legido-Quigley C; Thambisetty M
    PLoS Med; 2018 Jan; 15(1):e1002482. PubMed ID: 29370177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum.
    Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Rodriguez JL; Snellman A; Suárez-Calvet M; Zetterberg H; Blennow K; Schöll M;
    Brain; 2021 Feb; 144(1):325-339. PubMed ID: 33257949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease.
    Edmonds EC; Delano-Wood L; Galasko DR; Salmon DP; Bondi MW;
    J Alzheimers Dis; 2015; 47(1):231-42. PubMed ID: 26402771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease.
    Jack CR; Wiste HJ; Vemuri P; Weigand SD; Senjem ML; Zeng G; Bernstein MA; Gunter JL; Pankratz VS; Aisen PS; Weiner MW; Petersen RC; Shaw LM; Trojanowski JQ; Knopman DS;
    Brain; 2010 Nov; 133(11):3336-48. PubMed ID: 20935035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
    Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
    Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease.
    Baldeiras I; Santana I; Leitão MJ; Vieira D; Duro D; Mroczko B; Kornhuber J; Lewczuk P
    Alzheimers Res Ther; 2019 Jan; 11(1):2. PubMed ID: 30611311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging Techniques in Alzheimer's Disease: A Review of Applications in Early Diagnosis and Longitudinal Monitoring.
    van Oostveen WM; de Lange ECM
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.
    Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Liu E; Morris JC; Petersen RC; Saykin AJ; Schmidt ME; Shaw L; Siuciak JA; Soares H; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2012 Feb; 8(1 Suppl):S1-68. PubMed ID: 22047634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials.
    Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2017 Apr; 13(4):e1-e85. PubMed ID: 28342697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
    Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
    Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of the IWG-2 Diagnostic Criteria for Alzheimer's Disease to the ADNI.
    Wang HF; Tan L; Cao L; Zhu XC; Jiang T; Tan MS; Liu Y; Wang C; Tsai RM; Jia JP; Yu JT;
    J Alzheimers Dis; 2016; 51(1):227-36. PubMed ID: 26836176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigating the Association Between Verbal Forgetting and Pathological Markers of Alzheimer's and Lewy Body Diseases.
    Schaeffer MJ; Callahan BL;
    J Alzheimers Dis; 2019; 70(3):877-887. PubMed ID: 31282412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.